百利天恒BL-B01D1拟纳入突破性治疗品种

格隆汇
Sep 05, 2025

CDE官网显示,四川百利药业有限责任公司(百利天恒的全资子公司)1类新药注射用BL-B01D1拟纳入突破性治疗品种,用于铂耐药复发上皮性卵巢癌、输卵管癌或原发性腹膜癌患者。BL-B01D1是百利天恒自主研发的全球首创且进入3期临床的EGFR/HER3双抗ADC。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10